Rentschler Biopharma and Vetter team up to simplify processes

Companies agree that the key to tackling drug development complexity is collaboration.

The goal of the collaboration is to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.

"Our strategic collaboration is aimed at reducing complexity for our clients, with the joint overarching goal of bringing promising new therapies to patients with serious and rare diseases faster than before,” stated Prof. Dr Nikolaus F. Rentschler, Chairman of the Board of Rentschler Biopharma.

Senator h.c. Udo J. Vetter, Chairman of the Advisory Board of Vetter, added: “It is important for businesses to sometimes think outside the box. Pursuing future-oriented and innovative ideas is part of both of our companies’ DNA.”

The alliance of the two CDMOs will leverage Rentschler Biopharma’s experience in drug substance manufacturing, including bioprocess development and API production, and Vetter’s expertise in aseptic fill and finish and secondary packaging.

The companies have already identified opportunities where early and active exchange of know-how and best-practice will benefit both clients and their drug products. Over the next months, these opportunities will be further validated in pilot client projects with joint teams from both companies.

Dr Frank Mathias, CEO of Rentschler Biopharma, said. “Our collaboration holds great promise for further simplifying client solutions while expanding the boundaries of what is possible in biopharmaceutical production.”

Combining the two companies' experiences will enable them to deliver "new efficiencies" and "pathways that streamline the development and the supply chain" in ways that address the challenges of complexity companies across the industry are facing.